Advertisement
Singapore markets close in 7 hours 59 minutes

  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     

  • Nikkei

    38,269.95
    +717.79 (+1.91%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • Bitcoin USD

    66,748.01
    -306.43 (-0.46%)
     

  • CMC Crypto 200

    1,434.40
    +19.64 (+1.39%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Gold

    2,335.40
    -6.70 (-0.29%)
     

  • Crude Oil

    83.46
    +0.10 (+0.12%)
     

  • 10-Yr Bond

    4.5980
    -0.0520 (-1.12%)
     

  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     

  • Jakarta Composite Index

    7,110.81
    -7,073.82 (-49.87%)
     

  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Release date of six-month interim report (Q2) 2021 for ALK and audio cast

ALK Abello
·1-min read

On Wednesday, 11 August 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2021.

ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CEST) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.

Participants in the conference call are kindly requested to call in before 1.25pm (CEST). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the following participant pin code: 91659552#

ADVERTISEMENT

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,500 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment